Watching a short video before anti-VEGF eye injections
Impact of Procedural Video Viewing on Patients Undergoing Intravitreal Anti-VEGF Injections
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 182 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT07002372 on ClinicalTrials.gov |
What this trial studies
Adults receiving their first intravitreal anti-VEGF injection for retinal disease are randomly assigned to watch an educational video explaining the injection procedure or to receive standard care without the video. Anxiety is measured with the State-Trait Anxiety Inventory-State (STAI-S) before and after the injection, and clinicians record the presence and area of subconjunctival hemorrhage after the procedure. Patient satisfaction and immediate procedural experience are also collected. The trial is conducted at the Second Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China.
Who should consider this trial
Good fit: Ideal candidates are mentally competent adults receiving their first intravitreal anti-VEGF injection for retinal disease who can communicate without barriers and are willing to sign informed consent.
Not a fit: Patients with prior eye surgery, a best-corrected visual acuity in the better eye worse than 0.3, or a target eye complicated by neovascular glaucoma are excluded and unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the video could reduce procedure-related anxiety and decrease the frequency or size of subconjunctival hemorrhages, improving patient comfort and satisfaction.
How similar studies have performed: Video-based and other preprocedure education have reduced anxiety and increased satisfaction in other medical and ophthalmic settings, but direct evidence specific to intravitreal injections is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are receiving their first intravitreal injection of anti-VEGF medication due to retinal diseases * Mentally competent, and able to communicate without barriers * Willing to voluntarily sign an informed consent form. Exclusion Criteria: * History of previous eye surgery * Best-corrected visual acuity in the better eye worse than 0.3 * The target eye is complicated with neovascular glaucoma.
Where this trial is running
Hangzhou, Zhejiang
- Second Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Xiaoyun Fang, MD., PhD — Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study coordinator: Xiaoyun Fang, MD., PhD.
- Email: xiaoyunfang@zju.edu.cn
- Phone: + 86 13588411946
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.